<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">BDNF Therapies</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>BDNF Therapies</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Therapeutic</td>
</tr>
</table>
Brain-Derived Neurotrophic Factor (BDNF) therapies represent one of the most promising disease-modifying approaches in neurodegenerative disease treatment. BDNF is a critical neurotrophin that supports the survival, development, and function of [neurons](/entities/neurons) throughout the central and peripheral nervous systems. In Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and other neurodegenerative conditions, BDNF expression is significantly reduced, contributing to synaptic loss, neuronal dysfunction, and progressive cognitive and motor decline [1]. [@huang2001]
The therapeutic potential of BDNF stems from its ability to activate multiple downstream signaling pathways that promote neuroplasticity, protect against [apoptosis](/entities/apoptosis), enhance synaptic function, and support adult neurogenesis. This page provides a comprehensive overview of BDNF biology, therapeutic delivery strategies, clinical evidence, and future directions for BDNF-based therapies in neurodegeneration [2]. [@lu2013]
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">BDNF Therapies</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>BDNF Therapies</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Therapeutic</td>
</tr>
</table>
Brain-Derived Neurotrophic Factor (BDNF) therapies represent one of the most promising disease-modifying approaches in neurodegenerative disease treatment. BDNF is a critical neurotrophin that supports the survival, development, and function of [neurons](/entities/neurons) throughout the central and peripheral nervous systems. In Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and other neurodegenerative conditions, BDNF expression is significantly reduced, contributing to synaptic loss, neuronal dysfunction, and progressive cognitive and motor decline [1]. [@huang2001]
The therapeutic potential of BDNF stems from its ability to activate multiple downstream signaling pathways that promote neuroplasticity, protect against [apoptosis](/entities/apoptosis), enhance synaptic function, and support adult neurogenesis. This page provides a comprehensive overview of BDNF biology, therapeutic delivery strategies, clinical evidence, and future directions for BDNF-based therapies in neurodegeneration [2]. [@lu2013]
BDNF is a 119-amino acid polypeptide belonging to the neurotrophin family, which also includes nerve growth factor (NGF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4). Like other neurotrophins, BDNF is synthesized as a precursor (proBDNF) that can be proteolytically cleaved to form mature BDNF. Both forms are biologically active, with proBDNF primarily signaling through p75NTR receptors to promote apoptosis and synaptic depression, while mature BDNF preferentially activates TrkB receptors to support survival and plasticity [3]. [@lessmann2003]
TrkB (Tropomyosin receptor kinase B) is the high-affinity receptor for BDNF and NT-4. TrkB is a receptor tyrosine kinase that dimerizes and autophosphorylates upon BDNF binding, triggering downstream signaling cascades. Three TrkB isoforms exist: full-length TrkB (TrkB-FL) with catalytic activity, and two truncated isoforms (TrkB-T1, TrkB-T2) that act as dominant-negative regulators. The distribution of TrkB isoforms in different brain regions influences BDNF responsiveness [4]. [@patapoutian2001]
p75NTR (p75 neurotrophin receptor) binds all neurotrophins with low affinity and can signal independently or in complex with Trk receptors. When expressed without Trk, p75NTR can trigger apoptosis in the presence of proBDNF. However, when co-expressed with TrkB, p75NTR enhances BDNF binding affinity and promotes TrkB signaling. This complexity provides opportunities for targeted therapeutic intervention [5]. [@roux2002]
BDNF binding to TrkB activates multiple intracellular signaling pathways: [@hetman2000]
PI3K/Akt pathway: Following TrkB activation, PI3K is recruited to the receptor complex and generates phosphatidylinositol (3,4,5)-trisphosphate (PIP3), which activates Akt (protein kinase B). Akt phosphorylates numerous targets including [mTOR](/mechanisms/mtor-signaling-pathway), [GSK-3β](/entities/gsk3-beta), and FoxO transcription factors, promoting cell survival, protein synthesis, and metabolic regulation. The PI3K/Akt pathway is critical for BDNF-mediated neuroprotection against various insults [6]. [@grewal1999]
MAPK/ERK pathway: Ras activation following TrkB engagement leads to Raf, MEK, and ERK kinase cascade activation. ERK phosphorylates targets including transcription factors (CREB, Elk-1), ribosomal S6 kinase (RSK), and MAPK-interacting kinases (MNK). This pathway mediates the effects of BDNF on synaptic plasticity, [long-term potentiation](/mechanisms/long-term-potentiation) (LTP), and memory consolidation [7]. [@minichiello2006]
PLCγ pathway: Phospholipase C-gamma (PLCγ) is recruited to phosphorylated TrkB and hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to generate inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers calcium release from intracellular stores, while DAG activates protein kinase C (PKC). Both pathways regulate synaptic vesicle release, ion channel function, and gene expression [8]. [@poo2001]
BDNF plays essential roles in brain development and adult brain function: (1) neuronal survival during development through preventing apoptosis; (2) dendrite and axon growth and guidance; (3) synapse formation and maturation; (4) synaptic plasticity including [LTP](/mechanisms/long-term-potentiation)mechanisms/long-term-potentiation) and long-term depression (LTD); (5) adult hippocampal neurogenesis; (6) cognitive functions including learning and memory; and (7) regulation of mood and anxiety through limbic system circuits [9]. [@mitsumoto2002]
Direct administration of recombinant human BDNF has been tested in clinical trials for AD, ALS, and PD. While generally well-tolerated, this approach faces significant challenges including: (1) rapid degradation in circulation with half-life of only minutes; (2) poor blood-brain barrier penetration requiring intrathecal or intraventricular delivery; (3) potential immunogenicity of foreign protein; and (4) difficulty achieving therapeutic concentrations in target brain regions [10]. [@klein2019]
Viral vector-mediated BDNF gene therapy offers the potential for sustained BDNF expression in the brain. AAV vectors are the most commonly used delivery vehicles due to their ability to transduce neurons efficiently, long-term expression, and favorable safety profile. AAV2-BDNF has been tested in preclinical models showing protection of cholinergic neurons in AD models and dopaminergic neurons in PD models. Early-phase clinical trials have demonstrated safety, and further studies are planned [11]. [@jang2010]
Several small molecules that activate TrkB receptors have been developed to overcome the delivery challenges of protein-based therapies. 7,8-Dihydroxyflavone (7,8-DHF) is the most studied TrkB agonist, demonstrating brain penetration, TrkB activation, and neuroprotective effects in animal models of AD, PD, and traumatic brain injury. However, 7,8-DHF has modest potency and rapid metabolism, leading to the development of more optimized analogs [12]. [@longo2020]
Other TrkB agonist approaches include BDNF loop mimetics that mimic the active region of BDNF, antibody-based TrkB agonists with longer half-lives, and peptide agonists derived from BDNF sequences. While promising, none have reached late-stage clinical development [13]. [@kim2021]
Engineered cells secreting BDNF can be implanted into the brain to provide sustained BDNF delivery. Mesenchymal stem cells (MSCs) genetically modified to express BDNF have shown neuroprotective effects in preclinical models. Encapsulated cell therapy using devices containing BDNF-secreting cells allows for continuous release while enabling removal if needed [14]. [@cotman2007]
Physical exercise remains the most effective physiological stimulus for increasing BDNF expression. Aerobic exercise increases circulating BDNF levels through muscle release and hippocampal BDNF expression. Regular exercise has been shown to improve cognitive function, slow cognitive decline in AD, and enhance motor function in PD. The BDNF-mediated effects of exercise provide a non-pharmacological approach to neurotrophin enhancement [15]. [@nagahara2009]
BDNF is reduced in AD brains, particularly in the [hippocampus](/brain-regions/hippocampus) and [cortex](/brain-regions/cortex), correlating with cognitive decline. Therapeutic strategies under investigation include: (1) AAV-BDNF gene therapy to restore BDNF expression in affected brain regions; (2) TrkB agonists to enhance BDNF signaling; (3) exercise interventions to stimulate endogenous BDNF production; and (4) combination approaches including BDNF with other neurotrophic factors [16]. [@consroe2020]
BDNF supports the survival and function of dopaminergic neurons in the substantia nigra pars compacta. AAV-BDNF delivery has shown protection of dopaminergic neurons in toxin-based PD models. Clinical trials of BDNF gene therapy have been completed, demonstrating safety and showing evidence of biological activity in some patients [17]. [@bdnf2001]
BDNF has been tested in ALS clinical trials with mixed results. Intrathecal BDNF administration showed some evidence of slowing disease progression in early trials, but subsequent studies were inconclusive. Gene therapy approaches using AAV to deliver BDNF to motor neurons are under development [18]. [@bdnf2019]
Beyond neurodegenerative diseases, BDNF therapies have potential for psychiatric disorders. Ketamine's rapid antidepressant effects involve BDNF signaling, and BDNF val66met polymorphism affects treatment response. TrkB agonists are under development for treatment-resistant depression [19]. [@sanchez2021]
The [BBB](/entities/blood-brain-barrier) remains the major obstacle for BDNF therapy. Strategies to improve delivery include: (1) convection-enhanced delivery for direct brain infusion; (2) focused ultrasound-mediated BBB opening; (3) BBB-penetrant TrkB agonists; and (4) intrathecal delivery to cerebrospinal fluid [20]. [@tuszynski2019]
Achieving adequate BDNF expression in specific affected neuronal populations is challenging. Cell-type specific promoters in viral vectors and targeted infusion techniques can improve selectivity. Understanding which neuronal populations require BDNF restoration in each disease is critical [21]. [@kolb2022]
Combining BDNF therapy with other interventions may enhance efficacy. Noteworthy combinations include: (1) BDNF with exercise; (2) BDNF with other neurotrophic factors (GDNF, NGF); (3) BDNF with disease-modifying agents targeting protein aggregates; and (4) BDNF with symptomatic medications [22].
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate